🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wir freuen uns, Ihnen Prof. Dr. med. philipp ivanyi vorzustellen! Als internistischer Onkologe an der Medizinischen Hochschule in Hannover bringt er umfassende Expertise mit in unsere Videos zum #Urothelkarzinom und den Grundlagen der #Onkologie.  #oncologics #medicaleducation

Medical Monday: Präzisionsonkologie – ein spannendes Thema. Was ist das überhaupt? PD Dr. med. Philipp Ivanyi philipp ivanyi erklärt uns den Unterschied zwischen Präzisiononkologie und personalisierter Medizin. Schauen Sie mal bei oncologics rein! #medicalmonday #medicaleducation

🎥 In an #ISAL2025 interview, Florian Perner provided valuable insight into the mechanisms of resistance to menin inhibitors in AML and strategies to overcome resistance. Click here to watch: 👉 ow.ly/1spW50VuyyN 👈 #AMLsm #Leusm #Leukemia #HemOnc #ISAL25

NOW ONLINE! This review explains how targeting the KMT2A gene, a key driver in aggressive #Leukemias, with Menin inhibitors like Revumenib is showing promise. Also presented as a talk at the IJC Symposium on 14-Jan by Florian Perner 🔓➡️ doi.org/10.1002/ijc.35… Union for International #CancerControl

Congratulations Ari !!! Wonderful news!

We want You🫵

nature.com/articles/s4137…: Study published in Leukemia Journal, AI-guided analysis of real-world evidence from the Optum-database containing 82.960 PV patients to identify predictors of HU-RES. Great collaboration with J.J. Kiladjian, Martin Griesshammer GSG-MPN. Leibniz-Institut für Alternsforschung (FLI). #MHH.

NOW ONLINE! New review by Florian Perner et al. focuses on how targeted epigenetic drugs, like the emerging SWI/SNF‑focused compounds, are reshaping #CancerTherapy. Also presented at the IJC Symposium on 14-Jan by Prof. Michael Lübbert 🔓➡️ doi.org/10.1002/ijc.35… Union for International #CancerControl

Few days left to apply for a #postdoctoral position in my team investigating the pathomechanism of #IDH1 mutations at the interface of #metabolism and #epigenomics!

Fantastic keynote by Dominik Wolf at #IHEM2025 on CHIP and inflammation

Inspiring talk on eosinophilia by the great Andreas Reiter at #IHEM2025. GSG-MPN

📣 Today we have officially welcomed Dr Ari Melnick, the new Director of the Josep Carreras Institute. 💬 "I see us as a team united in our purpose to eradicate blood cancers." He has reaffirmed his commitment to scientific progress and collaborative growth in front of #IJC

Check out our new paper on embryonic macrophages in the bone marrow, now published in Nature Communications — made possible by a truly FANTASTIC TEAM! Claudia Waskow nature.com/articles/s4146… I first shared this story at ISEH 2023 online — and now it’s out!

Congratulations to the trial team :-) philipp ivanyi et al.

Joining the incomparable #ShannonElf Elf Lab 🇺🇦🏳️‍🌈🏳️‍⚧️⚧️👊🏾👊🏽🌈🟧 at the 17th #EuroNetMPN&MPNr meeting in #StGallen Vikas Gupta FlorianHeidel MPN World Peter Loffelhardt Huntsman Cancer Institute Neli Ulrich Ami Patel, MD Naveen Pemmaraju, MD

👉👉👉Delighted to share our brand new review article led by .⁦FlorianHeidel⁩ ➡️The evolving landscape of #epigenetic target molecules & therapies in myeloid cancers: focus on AML & MPN | ⁦Leukemia Journal⁩ #MPNSM #leusm nature.com/articles/s4137…

The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers - Naveen Pemmaraju (Naveen Pemmaraju, MD) FlorianHeidel Leukemia Journal oncodaily.com/science/epigen… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MyeloidCancers #AML

Dr. Florian Siegerist – formerly PhD student and postdoc in my group, now clinician scientist – will present our collaborative project with Prof. Florian Heidel and PD Tina Schnöder at the ERA - European Renal Association Meeting next week. 🔹 Title: Mesangial cell injury-aggravated CKD in

#ASCO25 Proud to be a key co-author on our ASCO Plenary Session #3 abstract presented by Andrew Kuykendall MD | #endcancer #VERIFY Ph 3 #MPNSM

#ASCO25 Prof Andreas Hochhaus | #ASC4START #asciminib met its primary endpoint vs nilotinib in newly dx patients with CML #leusm ASCO